Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 2, 2005, Pages 253-259

  Akhondzadeh, Shahin ^a,b   Safarcherati, Anosheh ^a   Amini, Homayoun ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

Adenosine; Allopurinol; Chronic schizophrenia; Haloperidol

Indexed keywords

ALLOPURINOL; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; INCREASED APPETITE; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; NERVOUSNESS; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RESTLESSNESS; RIGIDITY; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; URINE RETENTION;

EID: 13444259750     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.11.008     Document Type: Article

References (22)

1. A. Abi-Dargham Do we still believe in the dopamine hypothesis? New data bring new evidence Int. J. Neuropsychopharmacol. 1 2004 S1 S5 (suppl)
2. S. Akhondzadeh, E. Shasavand, H. Jamilian, O. Shabestari, and A. Kamalipour Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions J. Clin. Pharm. Ther. 25 2000 131 137
3. S. Akhondzadeh, A.K. Nejatisafa, H. Amini, B. Larijani, L. Kashani, F. Raisi, and A. Kamalipour Adjunctive estrogen treatment in women with chronic schizophrenia: a double blind, randomized and placebo controlled trial Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 1007 1012
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 4th ed. 1994 American Psychiatric Press Washington, DC DSM IV
5. J.M. Brundege, and T.V. Dunwiddie Role of adenosine as a modulator of synaptic activity in the central nervous system Adv. Pharmacol. 39 1997 353 391
6. M.G. Brunstein, E.S. Ghisolfi, F.L.P. Ramos, and D.R. Lara Clinical trial of allopurinol adjuvant therapy for poorly responsive schizophrenia Schizophr. Res. 67 2004 S142 S143
7. A. Darlsson, N. Waters, and M.L. Darlsson Neurotransmitter interactions in schizophrenia-therapeutic implications Biol. Psychiatry 15 1999 1388 1395
8. A. Erfurth, and M. Schmauss Perspectives on the therapy of neuropsychiatric diseases with adenosinergic substances Fortschr. Neurol. Psychiatr. 63 1995 93 98
9. R. Guieu, F. Couraud, J. Pouget, F. Sampieri, G. Bechis, and H. Rochat Adenosine and the nervous system: clinical implications Clin. Neuropharmacol. 19 1996 459 474
10. S. Ferre Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia Psychopharmacology 133 1997 107 120
11. A. Jablensky, N. Sartorius, and G. Ernberg Schizophrenia: manifestation, incidence and course in different cultures. A World Health Organization ten-country study Psychol. Med. 20 1991 1 97 (suppl)
12. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale for schizophrenia Schizophr. Bull. 13 1987 261 276
13. D.R. Lara, and D.O. Souza Schizophrenia: a purinergic hypothesis Med. Hypotheses 54 2000 157 166
14. Lara, D.R., Brunstein, M.G., Ghisolfi, E.S., Lobato, M.I., Belmonte-de-Abreu, P., Souza, D.O., 2001. Allopurinol augmentation for poorly responsive schizophrenia. Int. J. Clin. Psychopharmacol. 18, 235, 237.
15. M.R. Mohammadi, and S. Akhondzadeh Schizophrenia: etiology and pharmacotherapy IDrugs 4 2001 1167 1172
16. T.W. Stone Physiological roles for adenosine and adenosine 5-triphosphate in the nervous system Neuroscience 6 1981 523 550
17. T.W. Stone Purine receptor classification: a discussion point Trends Pharmacol. Sci. 5 1985 492 493
18. Y. Wada, H. Hasegawa, M. Nakamura, and N. Yamaguchi Anticonvulsant effect of allopurinol on hippocampal-kindled seizures Pharmacol. Biochem. Behav. 42 1992 899 901
19. S. Waters, A. Fae, J. Gondalia, J. Holm, L. Karlstrom, U. Nilsson, and O. Jonsson Effects of pretreatment with a xanthine oxidase inhibitor on free radical levels during carotid endarterectomy Free Radic. Res. 38 2004 283 293
20. World Medical Association Declaration of Helsinki, 2000. Ethical principles for medical research involving human subjects. Available at: http://www.wma.net.
21. I. Wright, and P. Woodruff Etiology of schizophrenia CNS Drugs 3 1995 126 144
22. P.G. Zagnoni, A. Bianchi, P. Zolo, R. Canger, C. Comaggia, and P. D'Alessandro Allopurinol as add-on therapy in refractory epilepsy: a double-blind placebo controlled study Epilepsia 35 1994 107 112